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A series of 1-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-3-chloro-4-(2-mercaptoquinolin-3-yl)azetidin-2-one
(7a-j) have been synthesized from the condensation of aromatic amines with N-phenylacetamide. The thione nucleus formed
from 2-chloroquionoline-3-carbadehyde using sodium sulphide in dimethyl formamide (DMF) was followed by the reaction
with pyrimidine amine to form the Schiff base intermediates. Attempt has been made to derive final azetidinone analogues from
Schiff bases by using chloroacetyl chloride. The newly synthesized analogues were examined for the antimicrobial activity against
some bacterial and fungal strains and in vitro antituberculosis activity against mycobacterium tuberculosis. These observations
provide some predictions to design further antibacterial and antituberculosis active compounds prior to their synthesis according
to molecular studies.
1. Introduction
In the family of heterocyclic compounds, nitrogen-contain-
ing heterocycles with a sulfur atom is an important class of
compounds in medicinal chemistry. There has been consid-
erable interest in the development of preparative methods for
the production of pyrimidines. This seems that pyrimidines
represent one of the most active classes of compounds,
possessing a wide spectrum of biological activities, namely,
diuretic [1], antitumor [2], anti-HIV [3], cardiovascular [4],
analgesic [5], calcium antagonist [6], anti-inflammatory [7],
CNS depressant activity [8], and antimalarialactivity [9].
Over the past few decades, a rapid increase in the oppor-
tunistic microbial infections as well as resistance of micro-
bial pathogens against current chemotherapeutics has been
observed. To the human civilization, spreading of such dead
diseases and epidemics is threatening. The rate of mortality
is at more serious stage within the patients having decreased
immunity and patients under organ transplantation [10].
Despite the numbers of antimicrobial chemotherapeutics
available, the natural occurrence of multidrug resistance in
recent years constitutes a substantial need for developing new
potentially active antimicrobial entities.
Antimicrobial agents have a chronicle of success in
controlling morbidity due to infectious diseases. But, as a
consequence of frequent use, bacterial and fungal resistance
to known classes of antimicrobial agent has become a global
problem in recent years and presents a continuous clinical
challenge [11–14]. Pyrimidine nuclei have been a source of
great interest to organic, medicinal, and material scientists
over many years, which are present in a number of biolog-
ically active organic compounds. Furthermore, Schiff base
[15, 16], azetidinone [17, 18], and thiazolidinone [19] have
also been found to possess promising antimicrobial activity.
In view of these observations, we thought that it would
be interesting to synthesize the substituted derivatives that
may lead to compounds with interesting antimicrobial and
antituberculosis profile.
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Scheme 1: Synthesis of 1-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-3-chloro-4-(2-mercaptoquinolin-3-yl)azetidin-2-one.
2. Experimental
All solvents and reagents were purchased from SigmaAldrich
Chemicals.Melting points were determined on an electrically
heated VMP-III melting point apparatus.The elemental anal-
yses of the compounds were performed on a Perkin Elmer
2400 Elemental Analyzer. The FT-IR spectra were recorded
using KBr discs on FT-IR 4100 Infrared spectrophotometer.
The NMR spectra were recorded using Bruker DRX 400
spectrometer at 400MHz for 1H NMR. Mass spectral data
were obtained by LC/MSD Trap XCT. Silica gel for column
chromatography was performed using Merck 7734 silica
gel and Merck-made TLC plates. Compounds 7a-j were
synthesized by the method summarized in Scheme 1.
2.1. General Procedure for the Synthesis of 2-Mercapto-quino-
line-3-carbaldehyde (4). The substituted 2-chloro-quinoline-
3-carbaldehyde (3) was prepared according to the literature
method [20]. The compound was taken (0.01mol) in dry
DMF (50mL) and sodium sulphide (0.015mol) was added
and stirred for 1-2 h at room temperature. On completion of
the reaction (monitored by TLC), the reaction mixture was
poured into crushed ice andmade acidic with acetic acid.The
product was filtered off, washed well with water, and dried
to give desired compound (4). The compounds were purified
by recrystallisation from DMF. Yield 83%, m.p. 283–285∘C.
IR (KBr) cm−1: 1687–1693 cm−1 (–CHO), 2575–2595 cm−1 (–
SH).
2.2. General Procedure for the Synthesis of (Z)-3-((Phenylimi-
no) Methyl) Quinoline-2-thiol(pyrimidine Amine) (6a–j).
Substituted 2-mercapto-quinoline-3-carbaldehyde (4) (0.01
mol) and pyrimidine amine (5) (0.01mol) were taken in
ethanol with catalytic amount of conc. H
2
SO
4
(2mL) and
heated to reflux for 6-7 h. After completion of the reaction
(TLC), the reactionmixture was poured onto crushed ice; the
solid mass separated out thus was filtered, washed with water,
and dried to give desired compounds 6a–j. The compounds
were purified by recrystallisation from ethanol.
2.3. General Procedure for Preparation of New Compounds
(7a–j). Amixture of substituted (Z)-3-((phenylimino)meth-
yl)quinoline-2-thiol(pyrimidine amine) (6a–j, 0.01mol)
and triethylamine (0.02mol) was dissolved in 1,4-dioxane
(50mL). To this well-stirred cooled solution, chloroacetyl
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chloride (0.02mol) was added dropwise during 30min. The
reactionmixture was refluxed for 10 hours.The triethylamine
hydrochloride salt formed was filtered to separate the salt.
The filtrate was concentrated to half of its initial volume and
then poured into crushed ice. The product obtained was
filtered, washed with water, and recrystallized from ethanol.
2.3.1. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(2-mercaptoquinolin-3-yl)azetidin-2-one
(7a). FT-IR (KBr, cm−1) ]: 2578 (S–H), 1731 (C=O), 1691
(C=N), 1582 (C=C). 1H NMR (DMSO-d
6
, 400MHz) 𝛿: 2.24
(s, 3H, Ar–CH
3
), 6.55 (s, 1H, CH–N), 6.91–7.83 (m, 14H, Ar–
H), 9.52 (s, 1H, NH), 11.05 (s, 1H, SH), 5.64 (d, 1H, CH–Cl).
MS (ESI) m/z: 524.12. Anal.calcd. for C
28
H
21
ClN
6
OS (in %):
C, 64.05; H, 4.03; N, 16.01. Found C, 64.15; H, 4.13; N, 16.11.
2.3.2. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(2-mercapto-8-methylquinolin-3-yl)azeti-
din-2-one (7b). FT-IR (KBr, cm−1) ]: 2569 (S–H), 1735
(C=O), 1689 (C=N), 1584 (C=C). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 2.31 (s, 6H, 2Ar–CH
3
), 5.46 (d, 1H, CH–Cl),
6.52 (s, 1H, CH–N), 7.12–7.82 (m, 13H, Ar–H), 9.53 (s, 1H,
NH), 11.03 (s, 1H, SH). MS (ESI) m/z: 540.10. Anal.calcd. for
C
29
H
23
ClN
6
OS (in %): C, 64.62; H, 4. 30; N, 15.59. Found C,
64.52; H, 4.40; N, 15.49.
2.3.3. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(2-mercapto-7-methylquinolin-3-yl)azeti-
din-2-one (7c). FT-IR (KBr, cm−1) ] : 2571 (S–H), 1729
(C=O), 1695 (C=N), 1586 (C=C). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 2.34 (s, 6H, Ar–CH
3
), 5.34 (d, 1H, CH–Cl),
6.61 (s, 1H, CH–N), 7.22–7.83 (m, 14H, Ar–H), 9.56 (s, 1H,
NH), 11.13 (s, 1H, SH). MS (ESI) m/z: 540.10. Anal.calcd. for
C
29
H
23
ClN
6
OS (in %): C, 64.62; H, 4. 30; N, 15.59. Found C,
64.49; H, 4.42; N, 15.45.
2.3.4. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(2-mercapto-6-methylquinolin-3-yl)azeti-
din-2-one (7d). FT-IR (KBr, cm−1) ]: 2568 (S–H), 1726
(C=O), 1693 (C=N), 1585 (C=C). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 2.14 (s, 9H, Ar–CH
3
), 5.51 (d, 1H, CH–Cl),
6.61 (s, 1H, CH–N), 7.17–7.80 (m, 12H, Ar–H), 9.56 (s, 1H,
NH), 11.13 (s, 1H, SH). MS (ESI) m/z: 540.05. Anal.calcd. for
C
29
H
25
ClN
6
OS (in %): C, 64.62; H, 4. 30; N, 15.59. Found C,
64.35; H, 4.34; N, 15.36.
2.3.5. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(2-mercapto-8-nitroquinolin-3-yl)azeti-
din-2-one (7e). FT-IR (KBr, cm−1) ]: 2571 (S–H), 1736
(C=O), 1693 (C=N), 1573 (C=C). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 2.41 (s, 3H, Ar–CH
3
), 5.49 (d, 1H, CH–Cl),
6.64 (s, 1H, CH–N), 7.19–7.73 (m, 13H, Ar–H), 9.53 (s, 1H,
NH), 11.23 (s, 1H, SH). MS (ESI) m/z: 571.02. Anal.calcd. for
C
28
H
20
ClN
7
O
3
S (in %): C, 59.00; H, 3.54; N, 17.20. Found C,
59.04; H, 3.58; N, 17.26.
2.3.6. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(2-mercapto-7-nitroquinolin-3-yl)azetidin-
2-one (7f). FT-IR (KBr, cm−1) ]: 2582 (S–H), 1740 (C=O),
1684 (C=N), 1591 (C=C). 1H NMR (DMSO-d
6
, 400MHz) 𝛿:
2.38 (s, 3H, Ar–CH
3
), 5.61 (d, 1H, CH–Cl), 6.66 (s, 1H, CH–
N), 7.17–7.61 (m, 13H, Ar–H), 9.41 (s, 1H, NH), 11.26 (s, 1H,
SH). MS (ESI) m/z: 571.12. Anal.calcd. for C
28
H
20
ClN
7
O
3
S
(in %): C, 59.00; H, 3.54; N, 17.20. Found C, 59.14; H, 3.54; N,
17.21.
2.3.7. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(2-mercapto-6-nitroquinolin-3-yl)azetidin-
2-one (7g). FT-IR (KBr, cm−1) ] : 2585 (S–H), 1736 (C=O),
1697 (C=N), 1578 (C=C). 1H NMR (DMSO-d
6
, 400MHz) 𝛿:
2.39 (s, 3H, Ar–CH
3
), 5.52 (d, 1H, CH–Cl), 6.61 (s, 1H, CH–
N), 7.18–7.63 (m, 13H, Ar–H), 9.50 (s, 1H, NH), 11.20 (s, 1H,
SH). MS (ESI) m/z: 571.02. Anal.calcd. for C
28
H
20
ClN
7
O
3
S
(in %): C, 59.00; H, 3.54; N, 17.20. Found C, 59.23; H, 3.51; N,
17.28.
2.3.8. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(8-chloro-2-mercaptoquinolin-3-yl)azeti-
din-2-one (7h). FT-IR (KBr, cm−1) ] : 2588 (S–H), 1737
(C=O), 1697 (C=N), 1575 (C=C). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 2.43 (s, 3H, Ar–CH
3
), 5.43 (d, 1H, CH–Cl),
6.69 (s, 1H, CH–N), 7.17–7.66 (m, 13H, Ar–H), 9.53 (s, 1H,
NH), 11.22 (s, 1H, SH). MS (ESI) m/z: 560.10. Anal.calcd. for
C
28
H
20
Cl
2
N
6
OS (in %): C, 60.11; H, 3.60; N, 15.02. Found C,
60.15; H, 3.64; N, 15.12.
2.3.9. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(7-chloro-2-mercaptoquinolin-3-yl)azeti-
din-2-one (7i). FT-IR (KBr, cm−1) ]: 2582 (S–H), 1743
(C=O), 1683 (C=N), 1585 (C=C). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 2.51 (s, 3H, Ar–CH
3
), 5.38 (d, 1H, CH–Cl),
6.65 (s, 1H, CH–N), 7.13–7.71 (m, 13H, Ar–H), 9.51 (s, 1H,
NH), 11.23 (s, 1H, SH). MS (ESI) m/z: 559.47. Anal.calcd. for
C
28
H
20
Cl
2
N
6
OS (in %): C, 60.11; H, 3.60; N, 15.02. Found C,
60.24; H, 3.73; N, 15.19.
2.3.10. 1-(3-(4-(Pyridin-3-yl)pyrimidin-2-ylamino)-4-methyl-
phenyl)-3-chloro-4-(6-chloro-2-mercaptoquinolin-3-yl)azeti-
din-2-one (7j). FT-IR (KBr, cm−1) ]: 2590 (S–H), 1734
(C=O), 1697 (C=N), 1586 (C=C). 1H NMR (DMSO-d
6
,
400MHz) 𝛿: 2.55 (s, 3H, Ar–CH
3
), 5.48 (d, 1H, CH–Cl),
6.67 (s, 1H, CH–N), 7.17–7.73 (m, 13H, Ar–H), 9.54 (s, 1H,
NH), 11.27 (s, 1H, SH). MS (ESI) m/z: 560.21. Anal.calcd. for
C
28
H
20
Cl
2
N
6
OS (in %): C, 60.11; H, 3.60; N, 15.02. Found C,
60.33; H, 3.61; N, 15.22.
2.4. Antioxidant Screening (In Vitro). Compounds 7a–j are
tested for antioxidant property by DPPH, NO, and H
2
O
2
methods.
2.5. DPPH Radical Scavenging Activity. The hydrogen atom
or electron donation ability of the compounds was measured
from the bleaching of the purple colored methanol solution
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of 1,1-diphenyl-1-picrylhydrazyl (DPPH). The spectrophoto-
metric assay uses the stable radical DPPH as a reagent. 1mL
of various concentrations of the test compounds (25, 50,
and 75 𝜇g/mL) in methanol was added to 4mL of 0.004%
(w/v) methanol solution of DPPH. After a 30min incubation
period at room temperature, the absorbance was read against
blank at 517 nm.The percent of inhibition (I%) of free radical
production from DPPH was calculated by the following
equation:
% of scavenging = [
(𝐴control − 𝐴 sample)
𝐴blank
] × 100, (1)
where 𝐴control is the absorbance of the control reaction
(containing all reagents except the test compound) and
𝐴 sample is the absorbance of the test compound. Tests were
carried out in triplicate.
2.6. Nitric Oxide (NO) Scavenging Activity. Nitric oxide scav-
enging activity was measured by slightly modified methods
of Green et al. [21] and Marcocci et al. [22]. The procedure is
based on the principle that sodium nitroprusside in aqueous
solution at physiological pH spontaneously generates nitric
oxide which interacts with oxygen to produce nitrite ions
that can be estimated using Griess reagent (1% sulfanilamide,
2% H
3
PO
4
, and 0.1% N-(1-naphthyl) ethylenediaminedi-
hydrochloride). Scavengers of nitric oxide compete with
oxygen, leading to reduced production of nitrite ions. 1mL
of sodium nitroprusside (10mmol) and 1.5mL of phosphate
buffer saline (0.2M, pH 7.4) were added to different concen-
trations (25, 50, and 75 𝜇g/mL) of the test compounds and
incubated for 150min at 25∘C and 1mL of the reaction mix-
ture was treated with 1mL of Griess reagent. The absorbance
of the chromatophore was measured at 546 nm. Nitric oxide
scavenging activity was calculated using (1).
2.7.Hydrogen Peroxide (H
2
O
2
) ScavengingActivity. TheH
2
O
2
scavenging ability of the test compound was determined
according to the method of Ruch et al. [23]. A solution of
H
2
O
2
(40mM) was prepared in phosphate buffer (pH 7.4).
25, 50, and 75 𝜇g/mL concentrations of the test compounds
in 3.4mL phosphate buffer were added to H
2
O
2
solution
(0.6mL, 40mM). The absorbance value of the reaction
mixture was recorded at 230 nm. The percent of scavenging
of H
2
O
2
was calculated using (1).
2.8. Antibacterial Activity. Antibacterial activity of the
synthesized compounds was determined against Gram-
positive bacteria (Bacillus subtilis MTCC 121, Staphylococcus
aureusMTCC 7443) and Gram-negative bacteria (Xanthom-
onascampestris MTCC 7908 and Escherichia coli MTCC
7410) in DMF by disc diffusion method on nutrient agar
medium [24]. The sterile medium (Nutrient Agar Medium,
15mL) in each petriplate was uniformly smeared with
cultures of Gram-positive and Gram-negative bacteria.
Sterile discs of 10mm diameter (Hi-Media) were placed in
the petriplates, to which 50 𝜇L (1mg/mL, i.e., 50 𝜇g/disc) of
different synthesized compounds was added. The treatments
also included 50 𝜇L of DMF as negative and bacteriomycin
and gentamycin as positive control for comparison. For each
treatment, three replicates were maintained. The plates were
incubated at 37 ± 2∘C for 24 h and the zone of inhibition was
determined.
2.9. Antifungal Activity. The synthesized compounds were
screened for their antifungal activity against Fusariumoxys-
porum MTCC 2480 in DMF by poisoned food technique
[25]. Potato DextroseAgar (PDA) medium was prepared and
about 15mL of PDA was poured into each petriplate and
allowed to solidify. 5mm disc of seven-day-old culture of
the test fungi was placed at the center of the petriplate
and incubated at 26∘C for 7 days. After incubation the
percentage inhibition was measured and three replicates
were maintained for each treatment. Nystatin was used as
standard. All the synthesized compounds were tested (at the
dosage of 500 𝜇L of the novel compounds/petriplate, where
concentration was 0.1mg/mL) by poisoned food technique.
2.10. Antituberculosis Activity. The compounds were
screened for antituberculosis activity under direction of the
U.S. National Institute of Health, NIAID division. All com-
pounds were initially screened againstMycobacterium tuber-
culosis strain H37Rv at single concentration of 6.25𝜇g/mL
in BACTEC 12B medium using a broth microdilution assay.
Compounds demonstrating growth inhibition ≥90% in
the primary screening were considered active. The active
compounds were retested by serial dilution beginning at
the concentration of 6.25 𝜇g/mL against Mycobacterium
tuberculosis H37Rv to determine the actual minimum
inhibitory concentration (MIC) in the BACTEC 460
radiometric system and BACTEC 12B medium. The MIC is
defined as the lowest concentration reducing fluorescence
to 90% of controls. The significance of this value depends
on several factors such as compound structure, novelty,
toxicity, and potential mechanism of action. INH (MIC =
0.025–0.05𝜇g/mL) and RMP (0.025–0.125 𝜇g/mL) were used
as positive control drugs [26].
3. Results and Discussion
3.1. Chemistry. Various routes have been developed for
the synthesis of functionalized quinolones; the Vilsmeier
[27] approach is found to be the most efficient. Thus, in
this communication, the synthesis of 2-chloroquinoline-3-
carbaldehyde 3 from N-aryl acetamides was followed by
reaction with Vilsmeier reagent and transformation into dif-
ferent functionalities. The required acetanilide 2 was readily
prepared from the reaction of corresponding amines with
acetic anhydride in aqueous medium. The Vilsmeier cycliza-
tion of acetanilide (2) was carried out by adding phosphorus
oxychloride to the N-aryl acetamides in DMF at 0–5∘C
followed by heating at 90∘C to afford substituted 2-chloro-3-
carbaldehyde (3) in good yield. The IR spectra of compound
(3) showed a strong absorption in the range of 1686–
1698 cm−1 for the aldehydic group. Thus, the chloro group
in few of the substituted 2-chloro-quinoline-3-carbaldehyde
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Table 1: Chemical structure and physical data of pyrimidine derivatives 7a–j.
Compound Structure Yield (%) mp (∘C)
7a
N
SH
N
Cl
O
N
H
N
N
N
CH3
72 256–258
7b
N
SH
N
Cl
O
N
H
N
N
N
H3C
CH3
74 259–251
7c
N
SH
N
Cl
O
N
H
N
N
NH3C
CH3
76 243-244
7d
N
SH
N
Cl
O
N
H
N
N
N
H3C
H3C
CH3
73 269–261
7e
N
SH
N
Cl
O
N
H
N
N
N
O2N
CH3
77 252–254
7f
N
SH
N
Cl
O
N N
N
NO2N
CH3
81 239–231
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Table 1: Continued.
Compound Structure Yield (%) mp (∘C)
7g SH
Cl
N N
O
N
H
N
N
N
O2N
CH3
73 234–236
7h SH
Cl
N N
O
N
H
N
N
N
Cl
CH3
75 245–247
7i
N
SH
N
Cl
O
N
H
N
N
NCl
CH3
82 232–235
7j N SH
N
Cl
O
N
H N
N
N
Cl
CH3
76 245–248
was investigated with various hetero nucleophiles. Due to
the replacement of chlorine by sulphur, sodium sulphide
in DMF was found to be an efficient reagent affording
nucleophilic substitution by sulphur and also providing scope
for further reaction and one-pot cyclisation.The substitution
was achieved in an hour at room temperature to afford thione
(4) in quantitative yield. Compound (4) showed prominent
peak of thione function group (–SH) at 2542–2626 cm−1.
Thus, carbaldehyde group in quinoline (4) was converted into
substituted quinoline Schiff base derivatives 6a–j in ethanol
at refluxed temperature.
Schiff base compounds 6a–j showed most prominent
peak of imine function group (–C=N–) at 1654–1660 cm−1.
The substituted Schiff base derivatives 6a–j was also react
with chloroacetylchloride in the presence of triethylamine
which act as a catalyst in 1,4-dioxane to undergo cyclization
to obtain pyrimidine azetidin-2-one derivatives 7a–j. The IR
spectrum of compounds 7a–j which showed sharp peak near
1723 cm−1 indicates the presence of ketone (–C=O) functional
group of azetidinone ring. A corresponding peak of C–N–CO
was observed at 1555–1575 cm−1. Chlorine functional group
exhibited a peak at 763–783 cm−1. Compounds structure and
physical data are depicted in the Table 1.
3.2. Antioxidant Activity. Compounds 7a–j are tested for
in vitro antioxidant property by 1,1-diphenylpicrylhydrazyl
(DPPH) [28, 29], nitric oxide (NO) [21, 22], and hydrogen
peroxide (H
2
O
2
) [23] methods which were summarized in
Tables 1–3, respectively. Compounds 7h, 7i, and 7j showed
good radical scavenging activity in all three methods due
to the presence of mild electron donating groups such as
chloro groups attached to the rings when compared with
Journal of Chemistry 7
Table 2: The in vitro antioxidant activity of 7a–j in DPPH method.
Compound Concentration (𝜇g/mL)
25 50 75 IC50
7a 69.30 ± 1.04 72.53 ± 0.85 77.84 ± 1.32 18.01 ± 1.05
7b 64.71 ± 1.45 67.44 ± 1.24 72.84 ± 1.56 19.35 ± 1.15
7c 63.88 ± 0.72 67.91 ± 1.29 71.48 ± 1.29 17.72 ± 0.63
7d 48.60 ± 0.65 52.86 ± 1.24 56.63 ± 0.55 17.21 ± 0.48
7e 52.71 ± 1.71 58.23 ± 1.00 61.37 ± 0.92 19.55 ± 1.21
7f 59.74 ± 1.18 64.42 ± 1.26 68.94 ± 0.88 23.72 ± 1.49
7g 68.43 ± 1.20 72.81 ± 1.45 74.93 ± 1.58 25.65 ± 1.05
7h 70.53 ± 0.20 74.25 ± 0.47 77.85 ± 0.65 20.94 ± 0.80
7i 72.41 ± 0.31 75.86 ± 0.63 78.36 ± 0.70 18.21 ± 1.06
7j 73.80 ± 0.10 77.42 ± 0.45 79.63 ± 0.46 16.92 ± 0.61
Ascorbic acid 82.70 ± 0.20 83.52± 0.38 85.52 ± 0.44 15.15 ± 0.49
Blank — — — —
(—) showed no scavenging activity. Values were the means of three replicates ± SD.
Table 3: The in vitro antioxidant activity of 7a–j in nitric oxide (NO) method.
Compound Concentration (𝜇g/mL)
25 50 75 IC50
7a 71.23 ± 0.85 74.85 ± 1.08 77.13 ± 1.43 17.55 ± 0.96
7b 68.34 ± 0.95 70.61 ± 1.39 74.18 ± 0.95 18.27 ± 1.05
7c 72.90 ± 0.85 74.06 ± 0.94 78.25 ± 1.06 17.14 ± 0.56
7d 64.37 ± 1.18 69.22 ± 1.57 74.69 ± 1.41 19.45 ± 1.27
7e 53.64 ± 1.39 56.49 ± 1.24 60.03 ± 0.71 23.35 ± 1.14
7f 62.04 ± 1.41 66.83 ± 1.56 70.92 ± 0.78 20.15 ± 0.98
7g 59.95 ± 1.55 60.47 ± 1.21 62.56 ± 1.31 20.49 ± 0.94
7h 73.03 ± 0.23 78.14 ± 0.45 82.44 ± 0.62 17.15 ± 0.95
7i 71.84 ± 0.17 76.29 ± 0.35 79.65 ± 0.54 17.39 ± 1.15
7j 75.23 ± 0.26 79.53 ± 0.37 82.64 ± 0.57 16.65 ± 0.60
Ascorbic acid 84.72 ± 0.18 85.96 ± 0.36 88.32 ± 0.52 14.71 ± 0.54
Blank — — — —
(—) showed no scavenging activity. Values were the means of three replicates ± SD.
Table 4: The in vitro antioxidant activity of 7a–j in hydrogen peroxide (H2O2) method.
Compounds Concentration (𝜇g/mL)
25 50 75 IC50
7a 61.05 ± 0.85 63.84 ± 1.58 68.22 ± 1.07 20.47 ± 1.23
7b 58.25 ± 1.17 62.31 ± 1.17 65.74 ± 1.47 21.22 ± 1.07
7c 60.26 ± 1.06 63.48 ± 1.27 67.84 ± 1.57 20.71 ± 0.54
7d 61.94 ± 1.32 64.51 ± 1.18 68.22 ± 1.07 20.15 ± 0.75
7e 45.02 ± 0.88 47.38 ± 1.17 50.44 ± 1.27 27.75 ± 0.65
7f 53.08 ± 0.89 56.61 ± 1.39 59.95 ± 0.78 23.54 ± 0.42
7g 51.37 ± 1.16 54.03 ± 0.86 58.12 ± 0.97 24.33 ± 1.04
7h 64.12 ± 0.27 67.44 ± 0.64 69.81 ± 0.69 19.49 ± 0.26
7i 66.25 ± 1.15 69.53 ± 1.31 71.68 ± 0.60 18.85 ± 0.60
7j 63.87 ± 0.30 65.49 ± 0.46 68.97 ± 0.65 19.57 ± 1.26
Ascorbic acid 76.41 ± 0.18 78.60 ± 0.33 82.39 ± 0.61 16.31 ± 0.31
Blank — — — —
(—) showed no scavenging activity. Values were the means of three replicates ± SD.
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the standard drug ascorbic acid. Compounds 7a, 7b, 7c, and
7d showed moderate antioxidant activity, whereas the other
compounds 7e, 7f, and 7g displayed mild activity. In general,
it was observed that halo substituted 7h, 7i, 7j, and the
unsubstituted compounds 7a, 7b, 7c, and 7d exhibited greater
activity when compared with the respective nitro-substituted
compounds. The IC
50
value of the standard ascorbic acid in
DPPH method was found to be 15.15 at 25 𝜇g/mL, whereas
the IC
50
values of the compounds 7h, 7i, and 7j were
found to be 17.72, 17.21, and 16.92 𝜇g/mL, respectively. Further
Tables 2–4 indicate that radical scavenging activity in DPPH,
nitric oxide, and hydrogen peroxide methods increases with
concentration.
3.3. Antimicrobial Activity. The investigation of antibacterial
screening data revealed that all tested compounds showed
antibacterial activity against four pathogenic bacterial strains.
It is worth to mention that pyrimidine analogues displayed
better activity against the mentioned microorganisms. It
was observed that the class of newly synthesized analogues
with electron withdrawing nitro and electron withdrawing
halo (–Cl, –F) substituent demonstrated potential antimi-
crobial properties. Among the series 7a–j, compounds 7h,
7i, and 7j showed excellent activity against Gram-positive
strain Staphylococcus aureus. Final pyrimidine analogues,
7h, 7i, and 7j, displayed strong inhibitory action against
Gram-positive Bacillus subtilis. Compounds 7e, 7f, and 7g
were found to contribute promising activity towards Gram-
negative strain Escherichia coli. All the remaining final
pyrimidine derivatives exerted good to moderate activity
profile, whereas some derivatives were found to display
weak activily profile. The antifungal bioas say results that
revealed those final pyrimidine derivatives 7f, 7g, and 7k
displayed antigrowth activity against Aspergillus niger. All
the remaining final pyrimidine derivatives were found to
demonstrate well to moderate activity profile (Table 5).
3.4. Antituberculosis Activity. In vitro tuberculosis activities
of compounds 7a–j were assessed against Mycobacterium
tuberculosis H37Rv. The results indicated that both pyrimi-
dine analogueswere active againstmycobacteria. Preliminary
antituberculosis screening results using BAC TECMGIT
method revealed that the final pyrimidine analogues 7i and
7j displayed the highest inhibition at a constant concentration
level (6.25 𝜇g/mL) againstM. tuberculosisH37Rv (Table 6).
4. Conclusion
In conclusion, a series of new 1-(3-(4-(pyridin-3-yl)pyrimi-
din-2-ylamino)-4-methylphenyl)-3-chloro-4-(2-mercapto-
quinolin-3-yl)azetidin-2-one derivatives, 7a–j, was synthe-
sized and their antimicrobial and antituberculosis activities
have been evaluated. Pyrimidine nucleus is one of the active
constituents present in many standard drugs and is known
to increase the pharmacological activities of the molecule.
The presence of substituted amines is also an instrumental in
contributing the net biological activity. In brief, high potency
has been observed with the final scaffolds in the form of
Table 5: In vitro antibacterial and antifungal activities of 7a–j.
Compound Zone of inhibition in diameter (mm)
B. subtilis S. aureus X. campestris E. coli
7a 22 19 21 24
7b 21 21 20 25
7c 20 22 22 23
7d 22 20 25 27
7e 23 19 30 30
7f 21 22 31 31
7g 22 22 32 33
7h 30 26 20 30
7i 31 25 23 24
7j 33 27 20
Bacteriocin — — 34 —
Gentamicin 35 30 — 35
Nystatin — — — —
Table 6: Antituberculosis activity of pyrimidine derivatives.
Compound Inhibition (%) MIC (lg/mL)
M. tuberculosis (H37Rv)
7a 58 >6.25
7b 59 >6.25
7c 67 >6.25
7d 58 >6.25
7e 72 >6.25
7f 68 >6.25
7g 71 >6.25
7h 82 >6.25
7i 80 6.25
7j 95 6.25
Rifampicin — 0.125
Isoniazid — 0.05
pyrimidine-azetidinones bearing various amines containing
halogen(s) such as chloro or fluoro and nitro functional
groups. The overall conclusion placed for synthesized
compounds is that most of the compounds showedmoderate
to promising activity as compared to standard drug against
all representative panel of bacterial, fungal, and tuberculosis
strains.
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